Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.

Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.